Asthma is increasingly recognised as a heterogeneous disease, with several phenotypes defined by clinical and inflammatory characteristics. Common phenotypes include allergic (eosinophilic, IgE-mediated), non-allergic (often neutrophilic or paucigranulocytic), late-onset adult asthma, obesity-associated asthma, and asthma with persistent airflow limitation.14 Identifying phenotypes supports individualised treatment strategies, particularly in those with severe asthma, and better long-term outcomes.
Steps 2 and 3: Maintenance and reliever therapy (MART)
Comorbid conditions can complicate asthma management. Assess for and help address factors such as allergic rhinitis, which affects up to 80% of people with asthma,24 as well as gastro-oesophageal reflux disease (GORD), anxiety, depression, obstructive sleep apnoea and smoking.
Huge change to vaping laws to smash recreational use
Huge changes are coming to vaping laws. What is changing, and what changes will affect pharmacists?
Reusable Respimat for Spiriva and Spiolto
Australia’s only soft mist inhaler, Respimat, is now available as a reusable device and is included on the PBS for asthma or COPD patients.
Just what the doctor ordered?
Ensuring the safe supply of medicines can sometimes necessitate robust discussions with prescribers. Here’s how to tackle them.
Self-assessment program to help pharmacists meet national standards
Ensure the services you provide are safe and effective by undertaking the PPS Quality Improvement and Self-Assessment Implementation Program.
New recommendations for patients with mild asthma
The latest version of the Australian Asthma Handbook includes a new treatment option for adults and adolescents with mild asthma.
New FIP report on pharmacy vaccinations around the world
Pharmacy-based vaccinations have grown by nearly 30% globally since 2016, according to a recent survey from the International Pharmaceutical Federation.
